ホーム › 膀胱癌 › マサチューセッツ州 › Boston
Boston、MAにおける膀胱癌の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、膀胱癌に関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
被験者募集中第3相
- Brigham and Women's Hospital, Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
被験者募集中第2相
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
被験者募集中第2相
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Patient-Centered Surgical Prehabilitation
被験者募集中健康なボランティア歓迎
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
被験者募集中第3相
- Dana Farber Cancer Institute ( Site 0783), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- Massachusetts General Hospital, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
被験者募集中
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
被験者募集中第2相
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
被験者募集中第2相
- Brigham and Women's Hospital, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Massachusetts General Hospital, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
被験者募集中第3相
- Massachusetts General Hospital Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
被験者募集中第1/2相
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
被験者募集中第2/3相
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
被験者募集中第3相
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- 他2件
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
被験者募集中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
被験者募集中
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
被験者募集中第3相
- Brigham and Women's Hospital, Boston
他の都市における膀胱癌の試験
- New York City, NY35件の研究
- Nashville, TN31件の研究
- Houston, TX31件の研究
- Dallas, TX27件の研究
- Washington, DC26件の研究
- Los Angeles, CA24件の研究
- Baltimore, MD24件の研究
- St. Louis, MO22件の研究
- Philadelphia, PA21件の研究
- Seattle, WA21件の研究
- Edison, NJ21件の研究
- Chicago, IL21件の研究
Bostonにおける他の研究
- 乳がん111件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）86件の研究
- 大腸癌63件の研究
- 転移性癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。